Use of the LEVA® Pelvic Health System for Fecal Incontinence

Last updated: April 14, 2025
Sponsor: University of Wisconsin, Madison
Overall Status: Completed

Phase

4

Condition

Fecal Incontinence

Bowel Dysfunction

Rectal Disorders

Treatment

The Leva Pelvic Health System

Clinical Study ID

NCT06152224
2023-1304
Protocol Version 10/12/2023
SMPH/OBGYN BENIGN GYN
A532810
Protocol Version 10/1/2024
  • Ages > 18
  • Female

Study Summary

The goal of this clinical trial is to learn about how the duration of use of The Leva Pelvic Health System® affects treatment of fecal incontinence in women. The main question it aims to answer is to test whether use of the The Leva Pelvic Health System® for 8 weeks is as good as using it for 16 weeks.

Participants will complete surveys, and use the Leva device.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adult, age ≥ 18years, assigned female at birth

  • Fecal incontinence, defined as any uncontrolled loss of liquid or solid fecalmaterial that occurs at least monthly over the last 3 months that is bothersomeenough to desire treatment

  • Able to stand to perform daily training for at least 3 minutes

  • Able to speak and read English due to Leva smartphone application availability inonly English at this time

  • Have an email address, owns a smartphone, and can download an app

Exclusion

Exclusion Criteria:

  • Inability to tolerate insertion of vaginal device (e.g., vaginal agenesis, vaginalstenosis, unremitting pelvic pain, within 12 weeks postpartum)

  • Current diagnosis of colorectal or anal malignancy

  • Diagnosis of uncontrolled inflammatory bowel disease

  • Current rectovaginal fistula or cloacal defect

  • Rectal prolapse (mucosal or full thickness)

  • Inability to utilize smart phone technology ("app" use)

  • Chronic Stool Types 6 or 7

  • Fecal impaction by exam

  • Stage 4 pelvic organ prolapse

  • Concurrent supervised anal sphincter exercise/pelvic floor muscle training with orwithout biofeedback

  • Presence of sacral neuromodulator

  • Pelvic floor surgery (including anal sphincteroplasty) within the past 3 months

  • Currently pregnant

Study Design

Total Participants: 39
Treatment Group(s): 1
Primary Treatment: The Leva Pelvic Health System
Phase: 4
Study Start date:
January 17, 2024
Estimated Completion Date:
April 11, 2025

Study Description

This study will assess whether 8 weeks of use of the Leva Pelvic Health System (Leva) is non-inferior to 16 weeks of use for the treatment of chronic fecal incontinence (symptoms >/= 3 months) in adults with a vagina. Participants will be instructed to complete pelvic floor muscle training using the Leva for 8 or 16 weeks.

The hypothesis is that 8 weeks of use of Leva is non-inferior to 16 weeks of use, assessed by a validated FI symptom severity survey. Surveys will be completed at 0 weeks, 16 weeks, and 24 weeks. Long-term surveys will be completed at 1 year and 2 years from enrollment.

Connect with a study center

  • University of Wisconsin

    Madison, Wisconsin 53705
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.